Objective: To investigate the outcomes of treatment strategies for proximal and iliofemoral deep vein thrombosis (DVT).
Venous thromboembolism (VTE) encompasses deep-vein thrombosis (DVT) and pulmonary embolism. VTE is the leading cause of lost disability-adjusted life years and the third leading cause of cardiovascular death in the world.
Bristol-Myers Squibb Company and Pfizer Inc. announced that the FDA approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban)...
Bristol-Myers Squibb Company and Pfizer Inc. announced that the European Commission has approved Eliquis (apixaban) for the treatment of Deep...
BMS and Pfizer Inc.have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Venous thromboembolism (VTE) describes the diagnoses of deep vein thrombosis (DVT) or pulmonary embolism (PE). DVT is the formation of thrombi in the deep veins, most commonly the large veins of the legs or pelvis.
This is a new portmanteau guideline designed to deal with a number of rarer thrombotic problems not dealt with in other guidelines but not meriting a guideline of their own.
Objective: These evidence-based guidelines from the American Society of Hematology (ASH) intend to support patients, clinicians, and others in decisions about treatment of VTE.
The present guideline document addresses acute deep vein thrombosis (DVT) of the lower extremity (unless otherwise stated), upper extremity DVT (UEDVT), superficial vein thrombosis (SVT), and thrombosis in unusual sites.
Clinicians have been more and more often encountering patients with venous thromboembolism (VTE), including pulmonary embolism and deep vein thrombosis, leading to the increased importance of VTE in daily clinical practice.